Michael Leviten
10Patents
4h-index
3Co-inventors
53Inventor score
Filing activity: Jul 11, 2001 → Feb 10, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9708394B2 | Anti-complement factor C1q antibodies and uses thereof | Physics | 7 | Active |
| US10227398B2 | Anti-complement factor C1q antibodies and uses thereof | Physics | 5 | Active |
| US10316081B2 | Humanized anti-complement factor C1Q antibodies | Physics | 5 | Active |
| US10590190B2 | Anti-complement factor C1q antibodies and uses thereof | Physics | 5 | Active |
| US10723788B2 | Anti-complement factor C1q Fab fragments and uses thereof | Physics | 3 | Active |
| US6653526B2 | Transgenic mice exhibiting increased susceptibility to seizures | Chemistry; Metallurgy | 2 | Expired |
| US10927167B2 | Anti-complement factor C1Q antibodies and uses thereof | Physics | 2 | Active |
| US7164055B2 | HSPC150-like gene disruptions, compositions and methods related thereto | Chemistry; Metallurgy | 0 | Expired |
| US11649279B2 | Anti-complement factor C1Q antibodies and uses thereof | Physics | 0 | Active |
| US11999779B2 | Anti-complement factor C1q Fab fragments and uses thereof | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.